

FORM PTO-1590 (Modified)  
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

## TRANSMITTAL LETTER TO THE UNITED STATES

PP01521.101

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/673798

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/US99/08802

22 April 1999

22 April 1998

## TITLE OF INVENTION

ENHANCING IMMUNE RESPONSES TO GENETIC IMMUNIZATION BY USING A CHEMOKINE

APPLICANT(S) FOR DO/EO/US

Xavier Paliard

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

## Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

Copy of Published Specification with International Search Report  
Written Opinion

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) <div style="font-size: 24pt; font-weight: bold; margin-top: 5px;">09/613798</div>	INTERNATIONAL APPLICATION NO. PCT/US99/08802	ATTORNEY'S DOCKET NUMBER PP01521.101
---	---	---

21. The following fees are submitted:

BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :		CALCULATIONS PTO USE ONLY															
<input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....	\$970.00	422 Rec'd PCT/PTO 19 OCT 2000															
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....	\$840.00																
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	\$690.00																
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....	\$670.00																
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) .....	\$96.00																
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>																	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <span style="float: right;"><input type="checkbox"/> 20 <input type="checkbox"/> 30</span>		<b>\$1,810.00</b>															
<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:20%;"></th> </tr> <tr> <td>Total claims</td> <td>27 - 20 =</td> <td>7</td> <td>x \$18.00</td> <td><b>\$126.00</b></td> </tr> <tr> <td>Independent claims</td> <td>2 - 3 =</td> <td>0</td> <td>x \$78.00</td> <td><b>\$0.00</b></td> </tr> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total claims	27 - 20 =	7	x \$18.00	<b>\$126.00</b>	Independent claims	2 - 3 =	0	x \$78.00	<b>\$0.00</b>	<b>\$0.00</b>
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE														
Total claims	27 - 20 =	7	x \$18.00	<b>\$126.00</b>													
Independent claims	2 - 3 =	0	x \$78.00	<b>\$0.00</b>													
Multiple Dependent Claims (check if applicable). <span style="float: right;"><input type="checkbox"/></span>		<b>\$0.00</b>															
<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$1,936.00</b>															
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <span style="float: right;"><input type="checkbox"/></span>		<b>\$0.00</b>															
<b>SUBTOTAL =</b>		<b>\$1,936.00</b>															
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <span style="float: right;"><input type="checkbox"/> 20 <input type="checkbox"/> 30</span>		<b>\$0.00</b>															
<b>TOTAL NATIONAL FEE =</b>		<b>\$1,936.00</b>															
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <span style="float: right;"><input checked="" type="checkbox"/></span>		<b>\$40.00</b>															
<b>TOTAL FEES ENCLOSED =</b>		<b>\$1,976.00</b>															
		<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:50%;">Amount to be refunded</td> <td style="width:50%;">\$</td> </tr> <tr> <td>charged</td> <td>\$</td> </tr> </table>	Amount to be refunded	\$	charged	\$											
Amount to be refunded	\$																
charged	\$																

☒ A check in the amount of **\$1,976.00** to cover the above fees is enclosed.  
☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.  
☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **03-1664** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:  

Anne S. Dollard  
 CHIRON CORPORATION  
 Intellectual Property - R338  
 PO Box 8097  
 Emeryville, California 94662-8097  
 US

SIGNATURE  


---

 Anne S. Dollard  
 NAME  


---

 43,935  
 REGISTRATION NUMBER  


---

 15 October 2000  
 DATE  


---

5/pts.  
422 Rec'd PCT/PTO 19 OCT 2000

## ENHANCING IMMUNE RESPONSES TO GENETIC IMMUNIZATION

This application claims the benefit of co-pending provisional application Serial No. 60/082,600 filed April 22, 1998, which is incorporated by reference herein.

### TECHNICAL AREA OF THE INVENTION

The invention relates to the area of immune responses to genetic immunization. More particularly, the invention relates to enhancing immune responses to DNA immunogens using immune co-stimulatory molecules.

### BACKGROUND OF THE INVENTION

The use of genetic immunization, or immunization with DNA encoding polypeptide immunogens, to prime immune responses is viewed as a promising vaccine strategy. This technology offers potential improvements compared to other types of vaccines, such as subunit proteins complexed with adjuvants or inactivated or attenuated viral preparations. In addition to the practical advantages of simplicity of construction and modification, injection of genetic material encoding for polypeptide immunogens results in synthesis of the immunogens in the host. Thus, these immunogens are presented to the host immune system with native post-translational modifications, structure, and conformation.

In mice, several DNA vaccines have been effective at inducing long-lived antibody and cytotoxic T lymphocyte (CTL) responses and have conferred protective immunity against a number of viruses, bacteria, parasites, and tumors (1-8). Various

approaches to enhance immune responses mediated by genetic immunization have been investigated. In addition to variations in dosage, route or boosting regimens, these variations include co-injection of polynucleotides encoding co-stimulatory molecules which improve immunogen presentation to lymphocytes, such as B7-1 or B7-2, or cytokines, such as GM-CSF, IL-2, IL-2, and IL-12, to create an optimal cytokine microenvironment for T cell priming (11-19). However, further enhancement of immune responses to genetic immunization is desirable for immunizing mammals, particularly humans, against immunogens such as virus- and tumor-specific immunogens.

Thus, there is a need in the art for methods of enhancing the immune responses to DNA immunogens.

#### SUMMARY OF THE INVENTION

It is an object of the invention to provide a method of enhancing an immune response to a DNA immunogen. This and other objects of the invention are provided by one or more of the embodiments described below.

One embodiment of the invention provides an immunogenic composition. The composition comprises a DNA immunogen and a chemokine or a polynucleotide encoding a chemokine.

Another embodiment of the invention provides a method of enhancing an immune response to a DNA immunogen in a mammal. A chemokine or a first polynucleotide encoding a chemokine and a DNA immunogen are administered to the mammal. An immune response to the DNA immunogen is thereby enhanced.

The present invention thus provides the art with the information that chemokines can be used to enhance an immune response of a mammal to a DNA immunogen. The invention can be used to, *inter alia*, to immunize or vaccinate a mammal against an infectious disease or a tumor.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

**Figure 1.** Figure 1 shows the immunization and bleeding schedules for animals immunized with HCV immunogens.

**Figure 2.** Figure 2 shows the immunization and bleeding schedules for animals immunized with granulocyte-macrophage colony-stimulating factor (GM-CSF).

**Figure 3.** Figure 3 shows the immunization and bleeding schedules for animals immunized with HCV immunogens and RANTES.

**Figure 4.** Figure 4 shows the immunization and bleeding schedules for animals immunized with HCV immunogens and macrophage inflammatory protein 1 $\alpha$  (MIP-1 $\alpha$ ).

**Figure 5.** Figure 5 shows the increased anti-HIV gag antibody titer in mice immunized with a plasmid encoding HIV gag and a plasmid encoding the chemokine B lymphocyte chemokine (BLC).

## **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

It is a discovery of the present invention that administration of a chemokine or a polynucleotide encoding a chemokine can be used to enhance an immune response in a mammal to a DNA immunogen. This method can be used, *inter alia*, to increase immunological resistance to pathogens, such as viruses and bacteria, and to tumor-associated immunogens.

Chemokines generally function as chemoattractants for cells which they recruit from the blood to sites of infection. Thus, administration of a chemokine, either together with or in addition to a DNA immunogen, effectively recruits various cell populations, including antigen presenting cells and effector cells, to the site of administration or its vicinity. Similarly, administration of a polynucleotide encoding a chemokine can result in local chemokine secretion which induces migration of antigen presenting cells and/or lymphocytes to the site of administration and which enhances immune responses to the DNA immunogen. Local chemokine secretion can also enhance the migration of cells which have taken up the DNA immunogen or

polypeptides encoded by the DNA immunogen to the lymph nodes, where priming of specific T cells can occur.

Chemokines which can be used in the method of the invention include, but are not limited to, B lymphocyte chemokine (BLC), IL-8, PBP/ $\beta$ -TG/NAP-2, macrophage inflammatory proteins MIP-1 $\alpha$ , MIP-1 $\beta$ , and MIP-3 $\alpha$ , macrophage chemoattractant and activating factor (MCP-1 or MCAF), MCP-2, MCP-3, I-309, C10, HCC-1, RANTES (regulated upon activation, normal T cell expressed and secreted), lymphotactin, SCM-1, eotaxin, MGSA, PF4, NAP-2, IP-10, ENA-78, EMF-1, GCP-2, SLC, ELC, and SDF-1. Certain chemokines may be more effective in combination with a particular DNA immunogen than others at stimulating an immune response; optimization of the DNA immunogen-chemokine combination can be carried out using routine assays in standard animal models (see Examples 1 and 2).

The immune response which is enhanced can be any response which is influenced by chemokines, including, but not limited to, antibody production or cytotoxic T lymphocyte (CTL) response resulting from chemoattraction and/or activation of antigen presenting cells, such as dendritic cells, macrophages, and monocytes, chemoattraction and/or activation of neutrophils, including eosinophils, and chemoattraction and/or activation of naive T cells, memory T cells, and pre-T cells to the thymus.

Measurement of enhanced immune responses can be carried out as is known in the art. For example, antibody titer can be measured by assays such as agglutination, immunoprecipitation, or ELISA.

Assays for chemotaxis relating to neutrophils are described in Walz *et al.* (1987), *Biochem. Biophys. Res. Commun.* 149: 755; Yoshimura *et al.* (1987), *Proc. Natl. Acad. Sci. USA* 84: 9233, and Schroder *et al.* (1987), *J. Immunol.* 139: 3474. Chemotaxis of lymphocytes can be assayed as described in Larsen *et al.*, *Science* 243: 1464; (1989) and Carr *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 3652 (1994).

Assays for chemotaxis of tumor-infiltrating lymphocytes are described in Liao *et al.* (1995), *J. Exp. Med.* 182: 1301; for hemopoietic progenitors, in Aiuti *et al.* (1997), *J. Exp. Med.* 185: 111; for monocytes, in Valente *et al.* (1988), *Biochem.* 27:

4162; and for natural killer cells, in Loetscher *et al.* (1996), *J. Immunol.* 156: 322, and in Allavena *et al.* (1994), *Eur. J. Immunol.* 24: 3233.

Attraction or activation of eosinophils, dendritic cells, basophils, and neutrophils, can also be measured. Assays for determining eosinophil attraction are described in Dahinden *et al.*, *J. Exp. Med.* 179: 751 (1994), Weber *et al.*, *J. Immunol.* 154: 4166 (1995), and Noso *et al.*, *Biochem. Biophys. Res. Commun.* 200: 1470 (1994). Attraction of dendritic cells can be measured as described, for example, in Sozzani *et al.*, *J. Immunol.* 155: 3292 (1995). Assays for attracting basophils are taught in Dahinden *et al.*, *J. Exp. Med.* 179: 751 (1994), Alam *et al.*, *J. Immunol.* 152: 1298 (1994), and Alam *et al.*, *J. Exp. Med.* 176: 781 (1992). Activation of neutrophils is taught in Maghazaci *et al.*, *Eur. J. Immunol.* 26: 315 (1996) and Taub *et al.*, *J. Immunol.* 155: 3877 (1995). Cytotoxic T lymphocyte assays can also be used to measure enhanced immune response to a DNA immunogen (see Example 1, below).

The DNA immunogen can be any contiguous sequence of deoxyribonucleotides encoding a polypeptide which is capable of eliciting an immune response. For example, polynucleotides encoding immunogenic polypeptides of viruses such as HIV viruses (*e.g.*, gag, pol, or env), herpes viruses (*i.e.*, HSV-1, HSV-2), Epstein-Barr virus, varicella-zoster virus, cytomegalovirus, and hepatitis B virus (HBV), hepatitis C virus (HCV), and human papilloma viruses (*i.e.*, HPV-16, -18, and -31) can serve as a DNA immunogen. DNA which encodes polypeptide immunogens of other infectious agents, such as bacteria, fungi, or yeast, can function as a DNA immunogen in the method of the invention. DNA which encodes polypeptides specifically expressed by a tumor, such as EGFRvIII, Ras, or p185<sup>HER2</sup>, or polypeptides which are expressed both by a tumor and by the corresponding normal tissue, can also function as a DNA immunogen. If desired, a DNA immunogen can comprise coding sequences for more than one immunogenic polypeptide.

A chemokine and a DNA immunogen can be administered to a mammal, preferably a human, by any means known in the art, including parenteral, intranasal, or intramuscular injection, or coated onto small metal projectiles and injected using a biological ballistic gun ("gene gun"). Alternatively, a chemokine and a DNA immunogen can be administered successively. The chemokine can be administered

prior to administration of the DNA immunogen, or the DNA immunogen can be administered prior to the administration of the chemokine.

A polynucleotide encoding the chemokine can also be administered. Preferably, a polynucleotide encoding the chemokine and a polynucleotide comprising the DNA immunogen are co-injected. The polynucleotides can also be administered successively, in any order. For co-administration, a single polynucleotide comprising both chemokine-encoding sequences and the DNA immunogen can be administered, or the DNA immunogen and the chemokine-encoding polynucleotide can be provided separately and mixed together prior to administration.

The invention also provides immunogenic compositions comprising a DNA immunogen and a chemokine or a polynucleotide encoding a chemokine. The composition can optionally comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those in the art. Such carriers include, but are not limited to, large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Pharmaceutically acceptable salts can also be used in compositions of the invention, for example, mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as well as salts of organic acids such as acetates, propionates, malonates, or benzoates. Compositions of the invention can also contain liquids, such as water, saline, glycerol, and ethanol, as well as substances such as wetting agents, emulsifying agents, or pH buffering agents. Liposomes, such as those described in U.S. 5,422,120, WO 95/13796, WO 91/14445, or EP 524,968 B1, can also be used as a carrier for a composition of the invention.

Compositions of the invention can be used as vaccine compositions, for example, to enhance an immune response of a mammal, including a human, to an infectious agent or a tumor. The particular dosages of chemokine and DNA immunogen which are sufficient to enhance an immune response to the DNA immunogen will vary according to the chemokine and DNA immunogen being used and the mammal to which the chemokine and DNA immunogen are being administered. The amounts of each active agent in the examples described below provide general guidance for the range of each component to be utilized by the



practitioner upon optimizing the method of the present invention for practice either *in vitro* or *in vivo*. Generally, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, or 5 mg of a chemokine protein, a polynucleotide encoding a chemokine, or a polynucleotide comprising a DNA immunogen will be administered to a large mammal, such as a baboon or a human.

Such ranges by no means preclude use of a higher or lower amount of a component, as might be warranted in a particular application. For example, the actual dose and schedule may vary depending on whether the compositions are administered in combination with other pharmaceutical compositions or depending on individual differences in pharmacokinetics, drug disposition, and metabolism.

The following are provided for exemplification purposes only and are not intended to limit the scope of the invention described in broad terms above.

#### **EXAMPLE 1**

*Co-administration of HCV immunogens and MIP-1 $\alpha$  increases lysis of autologous B cells infected with vaccinia virus encoding HCV polypeptide NS3*

*HCV immunogens.* Each plasmid comprises a CMV enhancer/promoter and is Kanamycin-resistant. Plasmids were prepared by an alkaline lysis method from *E. coli* bacteria and purified using Qiagen purification systems. After purification, plasmids were stored at -80 °C, at a concentration of 1 mg/ml.

Plasmid pCMVKm $\Delta$ NS comprises hepatitis C viral DNA encoding HCV polypeptides  $\Delta$ NS3, NS4, NS5a, and NS5b (immunogen for animal Group 1). Plasmid NS-GM2 encodes HCV polypeptides  $\Delta$ NS3, NS4, NS5b, NS5b, and hGM-CSF (immunogen for animal Group 2). Plasmid pCMVLhRantes encodes human RANTES protein. pCMVLhMIP1 $\alpha$  encodes MIP-1 $\alpha$ .

For the immunization protocols described below, pCMVKm $\Delta$ NS was premixed with either pCMVLhRantes (immunogen for animal Group 3) or pCMVLhMIP1 $\alpha$  (immunogen for animal Group 4). Each plasmid was at a concentration of 1 mg/ml of DNA, for a total of 2 mg/ml of DNA per mixed

immunogen.

*Injection of HCV immunogens into baboons.* On the day of injection, one vial (marked with the plasmid name and animal group) per animal was removed from the freezer, thawed at room temperature, and gently mixed. Each immunogen was injected both intramuscularly and intradermally. The total volume injected per animal was 1 ml.

The left and right tibialis anterior muscle was injected with 400  $\mu$ l of DNA for a total of 800  $\mu$ l intramuscular injection per baboon, using a 1 ml syringe. The immunogens were injected slowly, over about 10 seconds. After injection, the needle was removed slowly, to reduce leakage.

Each of two separate sites of the upper back was injected with 100  $\mu$ l of DNA for a total of 200  $\mu$ l intradermal injection per baboon, using a 0.3 ml U-100 Insulin syringe. The skin at the sites of injection was shaved. At each site, the needle was inserted the needle bevel up into the skin and then rotated 90 degrees so that the bevel pointed to the side. The 100  $\mu$ l was slowly injected over about 10 seconds. After injection, the needle was slowly rotated so that the bevel was up again, then withdrawn slowly to reduce leakage.

*Immunization and bleeding schedules for four groups of baboons.* Baboons in each of four groups were immunized and bled according to the following schedule. Group 1 (animals CK544, CK545, CK546, and CK547) received inoculations of pCMVKm $\Delta$ NS (HCV immunogens) and were bled according to the schedule in Figure 1. Group 2 (animals CK548, CK549, CK550, and CK551) received inoculations of NS-GM2 (HCV immunogens and GM-CSF) and were bled according to the schedule in Figure 2. Group 3 (animals CK552, CK553, CK554, and CK555) received inoculations of pCMVKm $\Delta$ NS and pCMVLhRantes (HCV immunogens and RANTES) according to the schedule in Figure 3. Group 4 (animals CK556, CK557, CK558, and CK559) received inoculations of pCMVKm $\Delta$ NS and pCMVLhMIP1a (HCV immunogens and MIP-1 $\alpha$ ) and were bled according to the schedule in Figure 4.

Immunizations were carried out as described in Example 2, above. At each of the times indicated in the bleeding schedules, blood was drawn from the femoral vein

while the baboons were under anesthesia (Ketamine®, 10 mg/ml). Blood was treated with heparin. B and T cells were isolated from these blood samples and used in the cytotoxic T lymphocyte assays described below.

CTL assays. Autologous B cell lines from each animal were established by transforming B cells with *H. papio*. Separate samples of peripheral blood mononuclear cells were restimulated with immortalized autologous B cells infected with a recombinant vaccinia virus that encodes each of the HCV immunogens (NS3, NS4, NS5a, and NS5b). Two weeks later, CD8<sup>+</sup> T lymphocytes were purified from the samples using magnetic beads.

The ability of T cells from each animal to lyse its autologous B cell line infected with vaccinia virus encoding the same immunogens used to immunize the animals was tested using a standard <sup>51</sup>Cr-release assay. Ratios of effector (T cells) to target (B cells) of 40:1, 10:1, and 2:1 were tested.

Percent lysis was calculated in each assay. A positive CTL response was noted if at least 10% more lysis occurred with homologous cells (stimulated with a vaccinia virus encoding an HCV immunogen) than with heterologous cells (stimulated with a vaccinia virus encoding an unrelated immunogen) for each of the two highest effector to target cell ratios tested.

Table I shows the number of animals with positive responses in a cytotoxic T lymphocyte assay.

Table I. Number of animals with CTL responses

Immunogen	No. of Animals
pCMVNS3-5	0/4
pCMVNS3-5 & MIP-1 $\alpha$	1/4
pCMVNS3-5 & RANTES	0/4

Table II shows percent lysis of target cells from animal CK556 after

restimulation. Homologous cells were stimulated with vaccinia virus encoding HCV polypeptide NS3.

Table II. Percent lysis of targets after restimulation (animal CK556)

	Effector:Target	Homologous <sup>1</sup>	Heterologous <sup>2</sup>
pre-immunization	40:1	2	11
pre-immunization	10:1	6	10
pre-immunization	2:1	7	6
2 weeks post 3rd immunization	40:1	27	<1
2 weeks post 3rd immunization	10:1	17	<1
2 weeks post 3rd immunization	2:1	11	<1

The results reported in Table II demonstrate that co-administration of HCV immunogens and the chemokine MIP-1 $\alpha$  resulted in an increased lysis of autologous B cells infected with vaccinia virus encoding HCV polypeptide NS3.

#### EXAMPLE 2

*Co-administration of HIV immunogens and BLC increases the titer of anti-p55gag*

Balb/c mice received bilateral injections into the anterior tibialis muscle of 10  $\mu$ g of a p55 plasmid, which encodes HIV gag, either alone or together with a total of 100  $\mu$ g of a plasmid encoding B lymphocyte chemokine (BLC; *Nature* 391, 799-803, 1998). Fifty  $\mu$ g of BLC-encoding plasmid were injected into each muscle.

The animals were bled at 3 and 6 weeks after immunization, and anti-p55gag antibody titer was measured by ELISA. Figure 5 shows that anti-gag antibody titer in

<sup>1</sup> stimulated with a vaccinia virus encoding HCV polypeptide NS3.

<sup>2</sup> stimulated with a vaccinia virus encoding an unrelated immunogen.

immunized mice is increased at three weeks after immunization and continues to increase up to at least six weeks.

**NUMBERED REFERENCES**

1. Ulmer, J., *et al.* 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein [see comments]. *Science* 259:1745-9.
- 5 2. Fynan, E., R. *et al.* 1993. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. *Proc Natl Acad Sci USA* 90:11478-82.
3. Cox, G., *et al.* 1993. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. *J Virol* 67:5664-7.
- 10 4. Sedegah, M., *et al.* 1994. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. *Proc Natl Acad Sci USA* 91:9866-70.
- 5 5. Barry, M., *et al.* 1995. Protection against mycoplasma infection using expression-library immunization. *Nature* 377-632-5.
- 6 6. Conry, R., *et al.* 1995. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. *Gene Ther* 2:59-65.
- 7 7. Syrengelas, A., *et al.* 1996. DNA immunization induces protective immunity against B-cell lymphoma. *Nat Med* 2:1038-1041.
- 20 8. Tascon, R., *et al.* 1996. Vaccination against tuberculosis by DNA injection. *Nat Med* 2:888-92.
- 9 9. Yasutomi, Y., *et al.* 1996. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. *J Virol* 70:678-81.
- 25 10. Letvin, M., *et al.* 1997. Potent protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. *Proc Natl Acad Sci USA* 94:9378-9383.
- 30 11. Xiang, Z., and H. Ertl. 1995. Manipulation of the immune responses to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. *Immunity* 2:129-35.
12. Conry, R., *et al.* 1996. Selected strategies to augment polynucleotide immunization. *Gene Ther* 3:67-74.

13. Irvine, K., *et al.* 1996. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. *J. Immunol* 156:238-45.
14. Chow, Y., *et al.* 1997. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B Surface antigen and interleukin-2. *J Virol* 71:169-78.
15. Iwasaki, A., *et al.* 1997. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. *J Immunol* 158:4591-601.
16. Kim, J., *et al.* 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. *J Immunol* 158:816-26.
17. Okada, E., *et al.* 1997. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. *J Immunol* 159:3638-47.
18. Geissler, M., *et al.* 1997. Enhancement of cellular and humoral immune responses to hepatitis C virus core proteins using DNA-based vaccines augmented with cytokine-expressing plasmids. *J Immunol* 158:1231-7.
19. Larsen, D., *et al.* 1998. Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice. *J Virol* 72:1704-8.
20. Butcher, E. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. *Cell* 67:1033-6.
21. Springer, T. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell* 76:301-14.
22. Butcher, E., and L. Picker. 1996. Lymphocyte homing and homeostasis. *Science* 272:60-6.
23. Schall, T., and K. Bacon. 1994. Chemokines, leukocyte trafficking, and inflammation. *Curr Opin Immunol* 6:865-73.

24. Taub, D., *et al.* 1993. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta *Science* 260:355-8.

25. Schall, T., *et al.* 1993. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. *J Exp Med* 177:1821-6.

26. Schall, T., *et al.* 1990. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. *Nature* 347:669-71.

27. Rot, A., *et al.* 1992. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. *J Exp Med* 176:1489-95.



**We claim:**

1. An immunogenic composition, comprising:  
a DNA immunogen; and  
a chemokine or a polynucleotide encoding a chemokine.
2. The immunogenic composition of claim 1 wherein the DNA immunogen comprises a polynucleotide encoding a viral immunogen.
3. The immunogenic composition of claim 2 wherein the polynucleotide encodes a hepatitis C virus non-structural polypeptide.
4. The immunogenic composition of claim 3 wherein the hepatitis C virus non-structural polypeptide is selected from the group consisting of NS3, NS4, NS5a, and NS5b.
5. The immunogenic composition of claim 2 wherein the polynucleotide encodes an HIV polypeptide.
6. The immunogenic composition of claim 5 wherein the HIV polypeptide is a gag polypeptide.
7. The immunogenic composition of claim 1 wherein the DNA immunogen comprises a polynucleotide encoding an immunogen expressed by a tumor.
8. The immunogenic composition of claim 1 wherein the chemokine is macrophage inflammatory protein 1 $\alpha$  (MIP-1 $\alpha$ ).
9. The immunogenic composition of claim 1 wherein the chemokine is B lymphocyte chemokine (BLC).
10. The immunogenic composition of claim 1 further comprising a pharmaceutically acceptable carrier.
11. A method of enhancing an immune response to a DNA immunogen in a mammal, comprising the step of:  
administering to the mammal (i) a chemokine or a first polynucleotide encoding a chemokine and (ii) a DNA immunogen, whereby an immune response to the DNA immunogen is enhanced.
12. The method of claim 11 wherein a chemokine is administered.

13. The method of claim 12 wherein the chemokine and the DNA immunogen are co-administered.

14. The method of claim 12 wherein the chemokine is administered prior to administration of the DNA immunogen.

15. The method of claim 12 wherein the DNA immunogen is administered prior to administration of the chemokine.

16. The method of claim 11 wherein a first polynucleotide encoding the chemokine is administered.

17. The method of claim 16 wherein the first polynucleotide and the DNA immunogen are co-administered.

18. The method of claim 16 wherein the polynucleotide is administered prior to administration of the DNA immunogen.

19. The method of claim 16 wherein the DNA immunogen is administered prior to administration of the first polynucleotide.

20. The method of claim 16 wherein a second polynucleotide which comprises (a) the first polynucleotide and (b) the DNA immunogen is administered.

21. The method of claim 11 wherein the chemokine is macrophage inflammatory protein 1 $\alpha$  (MIP-1 $\alpha$ ).

22. The method of claim 11 wherein the chemokine is B lymphocyte chemokine (BLC).

23. The method of claim 11 wherein the DNA immunogen comprises a polynucleotide which encodes a hepatitis C virus non-structural polypeptide.

24. The method of claim 23 wherein the hepatitis C virus non-structural polypeptide is selected from the group consisting of NS3, NS4, NS5a, and NS5b.

25. The method of claim 23 wherein the polynucleotide encodes an HIV polypeptide.

26. The method of claim 25 wherein the HIV polypeptide is a gag polypeptide.

27. The method of claim 11 wherein the mammal is a human.

28. The method of claim 11 wherein the immune response is an antibody response.

29. The method of claim 11 wherein the immune response is a cytotoxic T lymphocyte response.

FIG. 1

CHIRON #	SFBR#	SEX	Wt. kg
CX544	11117		
CX545	11281		
CX546	10832		
CX547	11272		
AVERAGE = #DIV/01			

STATUS	DATE	TOTAL TIME(WKS)	IMM#	IMMUNOGEN	BLEED #	BLEEDING SCHEDULE CYCLE	CHIRON CLOTTED BLOOD FOR SERUM (ml)	CHIRON HEPA- RINIZED BLOOD BY (ml)	OTHER ????	TOTAL PER TIME (ml)	% OF MAX BLED VOL	PERIOD
	NA		-	-		-	0	0		0		13
	NA		-	-		-	0	0		0		0
	NA		-	-		-	0	0		0		0
NEW	9/23/97	-2.0	-	-			0	0		0		0
	10/7/97	0.0	1	pCMV/KmANS	prebid 0		0	20		* 20	#DIV/01	0
	11/4/97	4.0	2	pCMV/KmANS			0	0		0		1
	11/18/97	6.0			1	8.0	0	0		0		1
	12/18/97	10.0			2	10.0	0	20		* 20	#DIV/01	1
	1/8/98	13.0	3	pCMV/KmANS		#REF!	0	0		* 20	#DIV/01	1
	1/20/98	16.0			3	#REF!	0	20		* 20		2
	2/17/98	19.0			4	#REF!	0	20		* 20		2
	3/17/98	23.0			5	#REF!	0	20		* 20	#DIV/01	2
	4/7/98	26.0	4	pCMV/KmANS		#REF!	0	0		0		3
	4/21/98	28.0			6	#REF!	0	20		* 20		3
	5/19/98	32.0			7	#REF!	0	20		* 20		3
	6/16/98	36.0			8	#REF!	0	20		* 20	#DIV/01	3
	TBD	TBD					0	0		0		999
	TBD	TBD					0	0		0		999
	TBD	TBD					0	0		0		999

2/5

FIG. 2

CHIRON #	SFER#	SEX	Wt. kg
CX548	11538		
CX549	8854		
CX550	9421		
CX551	10645		

AVERAGE = #DIV/01

STATUS	DATE	TOTAL TIME(WKS)	IMM#	IMMUNOGEN	BLEED#	BLEEDING SCHEDULE CYCLE	CHIRON CLOTED BLOOD FOR SERUM (ml)	CHIRON HEPA- RINIZED BLOOD BY (ml)	CHIRON ???	OTHER	TOTAL PER TIME (ml)	% OF MAX BLED VOL	PERIOD
	NA			-		-	0	0			0		13
	NA			-		-	0	0			0		0
	NA			-		-	0	0			0		0
NEW	9/25/97	-2.0											
	10/9/97	0.0	1	NS-GM2	prebid 0		0	20			*	20	0
	11/6/97	4.0	2	NS-GM2		0.0	0	0					1
	11/20/97	6.0				4.0	0	0					1
	12/18/97	10.0			1	8.0	0	20			*	20	1
	1/8/98	13.0	3	NS-GM2	2	10.0	0	20			*	20	1
	1/22/98	16.0				#REF!	0	0			*	20	1
	2/19/98	19.0			3	#REF!	0	20			*	20	2
	3/19/98	23.0			4	#REF!	0	20			*	20	2
	4/9/98	26.0	4	NS-GM2	5	#REF!	0	20			*	20	2
	4/23/98	28.0				#REF!	0	0					3
	5/21/98	32.0			6	#REF!	0	20			*	20	3
	6/18/98	38.0			7	#REF!	0	20			*	20	3
	TBD	TBD			8	#REF!	0	20			*	20	3
	TBD	TBD					0	0					999
	TBD	TBD					0	0					999
	TBD	TBD					0	0					999

3 / 5

FIG. 3

CHIRON #	SFBR#	SEX	Wt. kg
CX552	9047		
CX553	9801		
CX554	10593		
CX555	10399		
AVERAGE = #DIV/01			

STATUS	DATE	TOTAL TIME(WKS)	IMM#	IMMUNOGEN	BLEEDING SCHEDULE		CHIRON CLOTTED BLOOD SERUM (ml)	CHIRON HEPA- RINIZED BLOOD BY (ml)	OTHER ????	TOTAL PER TIME (ml)	% OF MAX BLED VOL	PERIOD
					BLEED#	"TIME"						
	NA		-	-		-	0	0		0	0	13
	NA		-	-		-	0	0		0	0	0
	NA		-	-		-	0	0		0	#DIV/01	0
NEW	10/7/97	-2.0	-	-			0	0				
	10/21/97	0.0	1	pCMWkMANS+pCMWkHranise	prebid 0	0.0	0	0		*	20	1
	11/18/97	4.0	2	pCMWkMANS+pCMWkHranise		4.0	0	0			0	1
	12/2/97	6.0			1	8.0	0	20		*	20	1
	12/30/97	10.0			2	10.0	0	20		*	20	1
	1/20/98	13.0	3	pCMWkMANS+pCMWkHranise		#REF!	0	0		*	20	1
	2/3/98	16.0			3	#REF!	0	20		*	20	2
	3/3/98	19.0			4	#REF!	0	20		*	20	2
	3/31/98	23.0			5	#REF!	0	20		*	20	2
	4/21/98	26.0	4	pCMWkMANS+pCMWkHranise		#REF!	0	0		*	20	3
	5/5/98	28.0			6	#REF!	0	20		*	20	3
	6/2/98	32.0			7	#REF!	0	20		*	20	3
	6/30/98	36.0			8	#REF!	0	20		*	20	3
	TBD	TBD					0				0	999
	TBD	TBD					0				0	999
	TBD	TBD					0				0	999

4 / 5

FIG. 4

STATUS	DATE	TOTAL TIME(WKS)	IMMUNOGEN	BLEEDING CYCLE BLEED #	CHIRON CLOTED BLOOD FOR SERUM (ml)	CHIRON HEPA- RINIZED BLOOD BY (ml)	OTHER ????	TOTAL PER TIME (ml)	% OF MAX BLED VOL	PERIOD
	NA		-	-	0	0		(ml)		13
	NA		-	-	0	0		0	0	0
	NA		-	-	0	0		0	0	0
NEW	10/9/97	-2.0	-	prebid 0	0	0		* 20	0	0
	10/23/97	0.0	1	pCMVkmANS+pCMVhMIP1a	0	0		0	0	1
	11/20/97	4.0	2	pCMVkmANS+pCMVhMIP1a	0	0		0	0	1
	12/4/97	6.0		1	6.0	0		* 20	0	1
	1/1/98	10.0		2	10.0	0		* 20	0	1
	1/22/98	13.0	3	pCMVkmANS+pCMVhMIP1a	0	0		* 20	0	1
	2/5/98	16.0		3	#REF!	0		0	0	2
	3/5/98	19.0		4	#REF!	0		* 20	0	2
	4/2/98	23.0		5	#REF!	0		* 20	0	2
	4/23/98	26.0	4	pCMVkmANS+pCMVhMIP1a	0	0		* 20	0	2
	5/7/98	28.0		6	#REF!	0		0	0	3
	6/4/98	32.0		7	#REF!	0		* 20	0	3
	7/2/98	38.0		8	#REF!	0		* 20	0	3
	TBD	TBD			0	0		0	0	999
	TBD	TBD			0	0		0	0	999
	TBD	TBD			0	0		0	0	999

AVERAGE = #DIV/0!




FIG. 5



Docket No.  
PP01521.101

## Declaration For Patent Application

### English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ENHANCING IMMUNE RESPONSES TO GENETIC IMMUNIZATION BY USING A CHEMOKINE

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 22 April 1999 as United States Application No. or PCT International

Application Number PCT/US99/08802

and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

N/A

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/082600

(Application Serial No.)

22 April 1998

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, CFR Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

N/A

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)


(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor

Paliard, XAVIER

Sole or first inventor's signature

Date  
18 October 2000

Residence

148 SATURN ST, #1 SAN FRANCISCO, CA 94114 CA

Citizenship

USA

Post Office Address

same as above

Full name of second inventor, if any

Second inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of third inventor, if any

Third inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of fourth inventor, if any

Fourth inventor's signature

Date

Residence

Citizenship

Post Office Address